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Primary small cell oesophageal carcinoma (SCOC) is rare, prognosis is poor and there is no established optimum treatment strategy.
It shares many clinicopathologic features with small cell carcinoma of the lung; therefore, a similar staging and treatment strategy was
adopted. Sixteen cases referred to Velindre hospital between 1998 and 2005 were identified. Patients received platinum-based
combination chemotherapy if appropriate. Those with limited disease (LD) received radical radiotherapy (RT) to all sites of disease
on completion of chemotherapy. Median survival of all patients was 13.2 months. Median survival of patients with LD was significantly
longer than those with extensive disease (24.4 vs 9.1 months, P¼0.034). This is one of the largest single institution series in the world
literature. Combined modality therapy using platinum-based combination chemotherapy and radical RT may allow a nonsurgical
approach to management, avoiding the morbidity of oesophagectomy. Prophylactic cranial irradiation is controversial, and should be
discussed on an individual basis.
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Primary small cell oesophageal carcinoma (SCOC) was first
described in 1952 by McKeown (1952), who reported two cases
at post mortem examination . It is a rare condition, accounting for
between 0.5 and 2.4% of all primary oesophageal malignancies
(Casas et al, 1997). Prognosis is poor and metastases are often
present at the time of diagnosis; patients presenting with disease
outside the oesophagus have a median survival of only 1 month
without treatment (Casas et al, 1997). Owing to its rarity, an
optimum treatment strategy has not been established, and various
combinations of surgery, radiotherapy (RT), and chemotherapy
have been described in the literature.
Small cell lung cancer (SCLC) is a far more common disease,
accounting for up to 20% of all primary lung cancers and it shares
many clinicopathologic features with SCOC. There is good
evidence that combination chemotherapy significantly increases
median survival compared to no systemic therapy or single agent
chemotherapy in SCLC (Girling, 1996; Agra et al, 2003). In
addition, in SCLC patients with limited disease (LD) and a
complete response to chemotherapy, consolidation thoracic
irradiation and prophylactic cranial irradiation (PCI) both
increase 3-year absolute survival by 5.4% (Pignon et al, 1992;
Auperin et al, 1999). Therefore, a similar staging and treatment
strategy for SCOC was adopted. We report our clinical experience
using this strategy and review the published literature on SCOC.
MATERIALS AND METHODS
All cases of SCOC referred to Velindre Cancer Centre, Southeast
Wales, between 1998 and 2005, were identified using an electronic
database holding information on all treated cancer patients
(Information System for Clinical Organisations, ISCO). Data were
collected retrospectively from ISCO and by case note review on
demographic details, performance status (PS), treatment, and
response to treatment. All patients were required to have a
histological diagnosis of small cell carcinoma according to WHO
criteria (WHO, 1982). Survival was recorded from the date of
histological diagnosis. Staging was analogous to that used in SCLC
as proposed by the Veterans’ Administration Lung Group; LD was
defined as a tumour mass contained within the oesophagus or
perioesophageal tissues, with or without regional lymph node
involvement, such that the disease can be encompassed within a
tolerable radiation therapy port, and extensive disease (ED)
included all other patients (Zelen, 1973). For the literature review,
the electronic databases MEDLINE, EMBASE, and Cancerlit were
searched using the key words oesophagus, oesophagus, small cell,
neuroendocrine, and gastrointestinal. Hand searching of journals,
relevant books, and review articles was also carried out. Survival
was calculated using the Kaplan–Meier method.
RESULTS
Sixteen patients were identified, and their clinical details are
summarised in Table 1. The age range of all patients was 48–81
years with a median age of 68.5 years and 12/16 (75%) patients
were female. Histological diagnosis was established by oesopha-
gogastroduodenoscopy and biopsy in all patients. In all cases, pure
SCOC was reported with no other histological subtypes identified.
In 8/16 (50%) patients selected, immunohistochemical staining
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swas performed to confirm the diagnosis. Neurone-specific enolase
was positive in three patients and CD56 in three patients,
supporting the diagnosis of small cell carcinoma. In two patients
immunohistochemistry was unhelpful, but a second opinion on the
cellular morphology supported the diagnosis of small cell
carcinoma. In 8/16 (50%) patients the diagnosis was made on
the classical histological appearance of small cell carcinoma and
immunohistochemistry was not deemed necessary. In total, 13/16
(81%) patients were staged with a CT scan of the chest and
abdomen. Two patients had abdominal ultrasound (Patients 9 and
14) and one patient was deemed too frail for staging investigations
(Patient 16). Only one patient (Patient 11) had a bone scan as part
of the initial staging investigations. A CT scan of the head was not
performed in any patient.
Performance status was recorded in 15/16 (93%) patients. In
total, 10/16 patients had a PS of 0–1, 4/16 had a PS of 2 and
1/16 had a PS of 4. In total, 13/16 patients had disease in the
lower-third of the oesophagus and 3/16 had disease in the middle-
third. No tumours were identified in the upper-third of the
oesophagus.
In total, 6/16 (38%) patients had LD, and 9/16 (56%) had ED.
Stage was not recorded in 1/16 (6%) patient.
Of those with ED, 7/9 (78%) patients had liver metastases at
the time of diagnosis. In total, 6/9 (67%) patients with ED were
given chemotherapy; all received four to six cycles of PE
(carboplatin AUC 5–6 intravenously (i.v.) in combination with
oral etoposide 3-weekly). Patients 13 and 15 received palliative RT
to the oesophagus following a partial response (PR) to chemother-
apy. Three patients (patients 9, 10, and 14) received no
chemotherapy because of poor PS, and were managed with best
supportive care. Patient 16 (unknown stage) was treated with
palliative RT only.
Five of the six patients with LD were given chemotherapy.
Patient 3 received six cycles of ICE (carboplatin AUC 6 i.v.
ifosfamide 3gm
 2 i.v. and oral etoposide 4-weekly). The other
patients received four to six cycles of either PE or CE (cisplatin
60–80mgm
 2 i.v. and oral etoposide 3-weekly). All five patients
received RT to the oesophagus given with curative intent following
a PR to chemotherapy. Patients 3 and 4 also received PCI. One
patient with LD (Patient 2) was treated at another cancer centre
Table 1 Clinical and treatment details of the 16 SCC oesophagus patients
PatientAgeSexPSStagePrimary SiteSite of metastases Chemo (cycles)ResponseOesophageal RT PCI Relapse site Survival (months)
1 77 F 0 LD Lower 4 PE PR 40Gy/15F 104, alive
2 71 M 1 LD Lower 44Gy/12F Local, nodal 19
3 59 M 0 LD Lower 6 ICE PR 40Gy/15F 30Gy/10F 48, alive
4 48 F 0 LD Lower 6 CE PR 50Gy/25F 30Gy/10FAscites 24
5 51 F 0 LD Mid 4 PE PR 45Gy/25F Local 9, alive
6 50 F 0 LD Mid 4 PE PR 50Gy/25F 30Gy/10FBone 14
7 53 F UK ED Lower Abdo nodes 4 PE PR 30Gy/15F Local 12
8 67 F 2 ED Lower Liver, spleen 4 PE UK UK 6
9 72 F 4 ED Lower liver 0.5
10 73 F 2 ED Lower Liver 1
11 71 M 1 ED Lower Liver 4 PE PR PD 10
12 72 F 1 ED Mid Liver, lungs, SCF 6 PE PR PD 30, alive
13 71 F 1 ED Lower Liver 4 PE PR 25Gy/10F Local, liver, brain13
14 65 F 2 ED Lower Liver PD 2
15 58 M 1 ED Lower Abdo nodes, pancreas4 PE PR 40Gy/15F 7, alive
16 81 F 2 UK Lower UK 8Gy/1F UK 7
Abdo¼abdominal; CE¼cisplatin and etoposide; DF¼disease-free; ED¼extensive disease; F¼female; ICE¼ifosphamide, cisplatin and etoposide; LD¼limited disease;
M¼male; PE¼carboplatin and etoposide; PCI¼prophylactic cranial irradiation; PS¼performance status; PR¼partial response; RT¼radiotherapy; SCF¼supraclavicular fossa;
UK, unknown
Median survival LD vs ED:
24.4 vs 9.1 months, p=0.034. 
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Figure 2 Overall survival of patients with limited vs ED.
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Figure 1 Overall survival of all patients with SCC oesophagus.
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swith radical RT alone. His subsequent treatment was carried out at
Velindre hospital.
Radiotherapy to the oesophagus was given 3–4 weeks after the
last cycle of chemotherapy. The dose given was 30–50Gy in 12–25
fractions over 2–5 weeks using megavoltage photons. Treatment
was 2D or 3D-planned to cover all areas of disease including any
involved lymph nodes. When used, PCI was given concurrently
with RT to the oesophagus. The median survival of all 16 patients
was 13.2 months (95% CI 7.7–18.7), and is shown in Figure 1.
To date, 7/9 (78%) patients with ED have died. Patients 12 and
15 are alive 30 and 7 months after diagnosis, respectively.
The median survival of all patients with ED is 9.1 months
(95%CI 3.3–14.8).
Of the six patients with LD, patients 1 and 3 are alive with no
evidence of recurrent disease, 104 and 48 months after diagnosis
respectively. Patient 5 is alive 9 months after diagnosis but has
relapsed locally. Patient 2 relapsed locally and died 19 months after
diagnosis. Patient 4 developed malignant ascites and patient 6
bone metastases, dying 24 and 14 months after diagnosis,
respectively. The median survival of all patients with LD was
24.4 months (95% CI 19.9–28.9), which was significantly longer
than those with ED (P¼0.034; Figure 2).
DISCUSSION
Primary SCOC is a relatively rare condition, and we have reported
one of the largest single-institution series in world literature. The
largest retrospective analysis has been carried out by Casas et al
(1997), who analysed data on 199 evaluable patients found in the
literature. They reported a male/female ratio of 1.57:1, with 95%
of tumours situated in the mid- and lower oesophagus. One-third
of cases were mixed tumours with squamous differentiation also
identified in addition to small sell carcinoma. Our series has a
male/ female ratio of 1:4, which is at variance with all other
published literature on SCOC. The relatively small sample size may
in part explain the difference, but a recent increase in the
proportion of female smokers may also play a role. We identified
no tumours in the upper-third of the oesophagus, concurring with
Casas et al, (1997). All tumours were pure small cell carcinoma
with no mixed tumours reported. However, none of our patients
had surgery, and the absence of other histological subtypes may
simply reflect the small size of the tissue samples examined at the
time of diagnosis. More than half of patients in our series had
metastatic disease at diagnosis, as in most other published series
(Casas et al, 1997). This is similar to SCLC, indicating SCOC is an
aggressive, systemic disease. The rarity of SCOC and absence of
randomised trials means the optimum treatment strategy remains
unclear.
For the treatment of LD with curative intent, RT alone has been
used; however, results generally have been disappointing and long-
term survivors are only rarely reported (Doherty et al, 1984;
Huncharek et al, 1995; Medgysey et al, 2000). The only patient in
our series treated with radical RT alone died 19 months after
diagnosis.
There are few reports of surgery being used as the sole treatment
modality and, as with RT, most institutional series report a poor
outcome with surgery alone. Hosokawa et al (2005) reported on
five LD patients treated with radical oesophagectomy alone, and
only one patient survived more than 24 months. Craig et al (1995)
reported on five patients treated with surgery alone, and only one
survived more than 12 months. Law et al (1994) treated three
patients with radical oesophagectomy with a median survival of
11.6 months.
The role of chemotherapy in SCLC is well established (Agra et al,
2005; Girling, 1996). Evidence suggests that extrapulmonary small
cell carcinoma is also a chemosensitive disease (Lester et al, 2006;
Levenson et al, 1981).There is a general consensus in the recent
literature that systemic chemotherapy should also be used in the
treatment of SCOC. Casas et al (1997) reported a median survival
of 20 months in those patients receiving systemic chemotherapy
compared to only 5 months in those having local treatment only.
Performance status was poorly reported in the series included in
the Casas review; good PS is a better prognostic factor in SCLC
(Bremnes et al, 2003), and it is reasonable to assume it is so in
SCC. Poor PS patients tend not be given chemotherapy, and the
longer survival in the chemotherapy group may therefore be owing
in part to the better PS of these patients. As a result of relatively
poor outcomes using local treatment only and the apparent
chemosensitivity of SCOC, combined modality treatment strategies
were developed. The MD Anderson Cancer Center reported on
four LD patients treated with chemotherapy followed by RT and/or
oesophagectomy. One patient remains alive and disease–free, 57
months after diagnosis (Medgysey et al, 2000). Craig et al (1995)
reported a patient surviving 96 months after oesophagectomy and
adjuvant chemotherapy. In our series, of the six patients with LD,
two are alive with no evidence of recurrent disease 47 and 79
months after diagnosis, respectively. Both received chemotherapy
followed by RT to all sites of disease.
Patients with LD were offered PCI at the discretion of the
treating oncologist. PCI in SCLC patients with LD has been shown
to decrease the incidence of brain metastases from 59 to 33%, and
increase 3-year absolute survival by 5.4%. The incidence of brain
metastases in SCOC is not known, and to our knowledge, no study
has been reported on the use of PCI in SCOC. To date, none of the
patients with LD has relapsed in the brain and only two patients
had PCI.
CONCLUSION
Caution should be applied in basing treatment strategies on
retrospective data, as poor record keeping and bias may influence
results. However, for localised disease it does seem that combined
modality therapy using platinum-based combination chemother-
apy and RT to the oesophagus may provide effective local control
and avoid the morbidity of extensive surgery. Oesophagectomy or
RT alone are probably inadequate, and if used, should be
combined with adjuvant or neoadjuvant platinum-based chemo-
therapy. The role of PCI is controversial, and should be discussed
with patients on an individual basis. For those patients prese-
nting with metastases, palliative chemotherapy may prolong
survival, and RT can be used for local control in selected good
PS patients.
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